Published in Neurology on January 01, 1997
Autologous Stem/Stromal Cells in Neurological Disorders and Disease (NDD) | NCT03297177
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Rapidly progressive dementia. Ann Neurol (2008) 3.00
Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology (2011) 2.42
Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol (2010) 2.19
Clinicopathological correlations in corticobasal degeneration. Ann Neurol (2011) 1.86
Rapidly progressive dementia. Neurol Clin (2007) 1.58
Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41
Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain (2008) 1.36
Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.32
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25
Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase (2004) 1.21
Neuroimaging and therapeutics in movement disorders. NeuroRx (2005) 1.17
Reading disorders in primary progressive aphasia: a behavioral and neuroimaging study. Neuropsychologia (2009) 1.15
Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord (2009) 1.10
Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol (2009) 0.96
Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther (2014) 0.96
The corticobasal syndrome-Alzheimer's disease conundrum. Expert Rev Neurother (2011) 0.95
Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord (2014) 0.93
Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. J Neurol (2008) 0.91
Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis Assoc Disord (2013) 0.90
Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol (1999) 0.89
Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open (2013) 0.89
Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry (1998) 0.88
Dyspraxia in a patient with corticobasal degeneration: the role of visual and tactile inputs to action. J Neurol Neurosurg Psychiatry (1999) 0.87
Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm (Vienna) (2007) 0.87
Corticobasal syndrome: Five new things. Neurol Clin Pract (2014) 0.87
Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis. Brain Behav (2015) 0.86
Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. J Neurol (2004) 0.86
Longitudinal deformation-based morphometry reveals spatio-temporal dynamics of brain volume changes in patients with corticobasal syndrome. PLoS One (2012) 0.85
Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders. Int J Mol Sci (2015) 0.85
Clinical Reasoning: a woman with rapidly progressive apraxia. Neurology (2013) 0.84
Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. J Mol Neurosci (2011) 0.83
α-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism. Ann Clin Transl Neurol (2014) 0.83
Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry (2002) 0.83
Corticobasal degeneration: structural and functional MRI and single-photon emission computed tomography. Neuroradiology (2003) 0.82
Discrepancy between clinical and pathological diagnoses of CBD and PSP. J Neurol (2005) 0.82
A disease-specific metabolic brain network associated with corticobasal degeneration. Brain (2014) 0.81
Visuoperception test predicts pathologic diagnosis of Alzheimer disease in corticobasal syndrome. Neurology (2014) 0.81
Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. J Neurol (2011) 0.81
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Curr Treat Options Neurol (2016) 0.80
New perspective on parkinsonism in frontotemporal lobar degeneration. J Mov Disord (2013) 0.79
Sleep Disorders in Atypical Parkinsonism. Mov Disord Clin Pract (2014) 0.79
Neuroimaging in dementia. Semin Neurol (2008) 0.78
Cortical Activation During Levitation and Tentacular Movements of Corticobasal Syndrome. Medicine (Baltimore) (2015) 0.77
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener (2017) 0.75
A 64-year old man presenting with carotid artery occlusion and corticobasal syndrome: a case report. J Med Case Rep (2011) 0.75
Biomarkers in the primary progressive aphasias. Aphasiology (2014) 0.75
Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology (2017) 0.75
The feasibility of white matter volume reduction analysis using SPM8 plus DARTEL for the diagnosis of patients with clinically diagnosed corticobasal syndrome and Richardson's syndrome. Neuroimage Clin (2014) 0.75
Differentiating atypical parkinsonian syndromes--a way forward? Brain Behav (2015) 0.75
Approach to atypical Alzheimer's disease and case studies of the major subtypes. CNS Spectr (2017) 0.75
The place of perceptual analysis of dysarthria in the differential diagnosis of corticobasal degeneration and Parkinson's disease. J Neurol (2005) 0.75
Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep (2017) 0.75
Measuring disease progression in corticobasal syndrome. J Neurol (2014) 0.75
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ (2000) 7.36
The intraclass correlation coefficient as a measure of reliability. Psychol Rep (1966) 7.27
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med (1993) 5.84
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain (2009) 5.03
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry (2000) 3.96
Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg (2000) 3.83
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Ann Surg (1998) 3.43
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
On the methods and theory of reliability. J Nerv Ment Dis (1976) 3.35
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology (2000) 3.23
A prospective study on fish bone ingestion. Experience of 358 patients. Ann Surg (1990) 3.19
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 3.03
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol (1989) 2.91
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Essential tremor: clinical correlates in 350 patients. Neurology (1991) 2.89
Education and change in cognitive function. The Epidemiologic Catchment Area Study. Ann Epidemiol (1995) 2.87
Tissue-specific expression of a chicken calmodulin pseudogene lacking intervening sequences. Proc Natl Acad Sci U S A (1983) 2.86
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
The morbidity and mortality of vermiculite miners and millers exposed to tremolite-actinolite: Part I. Exposure estimates. Am J Ind Med (1987) 2.66
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Heterotopic pancreas. Review of a 26 year experience. Am J Surg (1986) 2.61
Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology (2007) 2.61
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
The ovalbumin gene: alleles created by mutations in the intervening sequences of the natural gene. Cell (1979) 2.56
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology (2000) 2.48
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Psychogenic myoclonus. Neurology (1993) 2.39
Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 2.38
Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg (1995) 2.37
The impact of depressive symptoms in early Parkinson disease. Neurology (2007) 2.37
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull (1974) 2.25
Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery (1998) 2.22
Paroxysmal dyskinesias: clinical features and classification. Ann Neurol (1995) 2.21
Sporadic Creutzfeldt-Jakob disease mimicking nonconvulsive status epilepticus. Neurology (2010) 2.17
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
Phylogenetic characterization of novel transport protein families revealed by genome analyses. Biochim Biophys Acta (1999) 2.15
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg (1997) 2.15
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Discrete enhancer elements mediate selective responsiveness of enhancer of split complex genes to common transcriptional activators. Dev Biol (1999) 2.07
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
The chick ovomucoid gene contains at least six intervening sequences. Nature (1979) 2.01
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain (1999) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Chicken calmodulin genes. A species comparison of cDNA sequences and isolation of a genomic clone. J Biol Chem (1983) 1.98
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
Hepatectomy with an ultrasonic dissector for hepatocellular carcinoma. Br J Surg (1996) 1.97
Delayed-onset progressive movement disorders after static brain lesions. Neurology (1996) 1.96
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology (1998) 1.96
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med (1994) 1.93
Early versus delayed laparoscopic cholecystectomy for treatment of acute cholecystitis. Ann Surg (1996) 1.92
Assignment of the alpha 1-antitrypsin gene and a sequence-related gene to human chromosome 14 by molecular hybridization. Am J Hum Genet (1983) 1.91
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Arch Gen Psychiatry (1989) 1.89
Neuroaxonal dystrophy in man: character and natural history. Acta Neuropathol (1971) 1.89
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Hemifacial spasm: clinical findings and treatment. Muscle Nerve (1998) 1.88
Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol (1983) 1.87